ADMA Biologics
ADMA · Biotechnology
$10.68
2.5%Roivant Sciences
ROIV · Biotechnology
$36.49
2.6%The short version
- ADMA Biologics is the larger business, with $510M of revenue in fiscal 2025 against $8.3M for Roivant Sciences, about 61 times as much.
- ADMA Biologics grew revenue faster (19.6%, against −71.6%).
- ADMA Biologics kept more of each dollar of sales as operating profit (37.5% operating margin, against −6,235.7% operating margin).
- ADMA Biologics turned more of its sales into free cash flow (5.5% FCF margin, against −9,183.5% FCF margin).
- ADMA Biologics earned a higher return on the capital invested in it (39.5%, against −62.6%).
| Latest fiscal year | ADMA · FY25 | ROIV · FY25 |
|---|---|---|
| Size | ||
| Market cap | $2.5B | $26.3B |
| Revenue | $510M | $8.3M |
| Free cash flow | $27.8M | −$759M |
| Net income | $147M | −$300M |
| Growth | ||
| Revenue growth | 19.6% | −71.6% |
| 5-year growth | 64.6% | −19.0% |
| Share count change | 0.6% | −4.4% |
| Profitability | ||
| Gross margin | 57.4% | — |
| Operating margin | 37.5% | −6,235.7% |
| Net margin | 28.8% | −3,629.2% |
| FCF margin | 5.5% | −9,183.5% |
| Return on capital | 39.5% | −62.6% |
| Return on equity | 35.6% | −6.5% |
| Balance sheet | ||
| Net debt | −$15.5M | −$4.3B |
| Net debt / EBITDA | −0.1x | — |
| Dividends and buybacks | $31.9M | $0.0M |
| Valuation & quality | ||
| P/E | 15.3x | — |
| Piotroski F-score | 5 | 1 |
FY16
ADMA $10.7M
ROIV —
FY17
ADMA $22.8M
ROIV —
FY18
ADMA $17.0M
ROIV —
FY19
ADMA $29.3M
ROIV —
FY20
ADMA $42.2M
ROIV $23.8M
FY21
ADMA $80.9M
ROIV $55.3M
FY22
ADMA $154M
ROIV $31.5M
FY23
ADMA $258M
ROIV $32.7M
FY24
ADMA $427M
ROIV $29.1M
FY25
ADMA $510M
ROIV $8.3M
ADMA
ROIV
FY16
ADMA −162.6%
ROIV —
FY17
ADMA −172.7%
ROIV —
FY18
ADMA −355.0%
ROIV —
FY19
ADMA −141.1%
ROIV —
FY20
ADMA −153.8%
ROIV −4,500.5%
FY21
ADMA −72.1%
ROIV −2,444.8%
FY22
ADMA −25.6%
ROIV −2,875.9%
FY23
ADMA 8.4%
ROIV 13,746.9%
FY24
ADMA 32.6%
ROIV −3,453.3%
FY25
ADMA 37.5%
ROIV −6,235.7%
ADMA
ROIV
FY16
ADMA −$18.3M
ROIV —
FY17
ADMA −$40.0M
ROIV —
FY18
ADMA −$64.8M
ROIV —
FY19
ADMA −$80.0M
ROIV —
FY20
ADMA −$115M
ROIV −$558M
FY21
ADMA −$126M
ROIV −$695M
FY22
ADMA −$73.4M
ROIV −$856M
FY23
ADMA $4.0M
ROIV −$767M
FY24
ADMA $110M
ROIV −$844M
FY25
ADMA $27.8M
ROIV −$759M
ADMA
ROIV
FY16
ADMA —
ROIV —
FY17
ADMA —
ROIV —
FY18
ADMA —
ROIV —
FY19
ADMA —
ROIV —
FY20
ADMA −82.2%
ROIV —
FY21
ADMA −29.7%
ROIV —
FY22
ADMA −15.8%
ROIV −286.2%
FY23
ADMA 8.1%
ROIV —
FY24
ADMA 52.2%
ROIV —
FY25
ADMA 39.5%
ROIV −62.6%
ADMA
ROIV
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.